Kinase-inhibitors for iodine-refractory differentiated thyroid cancer: still far from a structured therapeutic algorithm-Reference-Cited by-同舟云学术

Kinase-inhibitors for iodine-refractory differentiated thyroid cancer: still far from a structured therapeutic algorithm

Published:2021-06 Issue: Volume:162 Page:103353
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Marotta Vincenzo,Chiofalo Maria Grazia^ORCID,Di Gennaro Francesca,Daponte Antonio^ORCID,Sandomenico Fabio^ORCID,Vallone Paolo,Costigliola Luciana^ORCID,Botti Gerardo,Ionna Franco,Pezzullo Luciano

Funder

Ministry of Health

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference109 articles.

1. Integrated genomic characterization of papillary thyroid carcinoma;Agrawal;Cell,2014

2. Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: dutch real-life data;Aydemirli;Eur. J. Endocrinol.,2019

3. The selectivity of protein kinase inhibitors: a further update;Bain;Biochem. J.,2007

4. Lenvatinib in advanced radioiodine-refractory thyroid Cancer - a retrospective analysis of the swiss lenvatinib named patient program;Balmelli;J. Cancer,2018

5. Multiple Technology Appraisal. Lenvatinib and Sorafenib for Treating Differentiated Thyroid Cancer after Radioactive Iodine. Company Submission to NICE. Company Submission to NICE;Bayer HealthCare,2017

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival Predictors of Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib in Real Life;The Journal of Clinical Endocrinology & Metabolism;2024-03-19

2. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study;BMC Endocrine Disorders;2024-02-22

3. Association of DNA Promoter Methylation and BRAF Mutation in Thyroid Cancer;Current Oncology;2023-03-02

4. Disulfiram/Cu Kills and Sensitizes BRAF-Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways;International Journal of Molecular Sciences;2023-02-08

5. Molecular and Other Ancillary Tests;The Bethesda System for Reporting Thyroid Cytopathology;2023